ReP USP - Resultado da busca

Artigo de periodico
Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells (2022)
Fernandes, Jaqueline Cristina; Fenerich, Bruna Alves ; Silva, Antônio Bruno Alves; Fonseca, Natasha Peixoto ; Silva, Juan Luiz Coelho ; Scheucher, Priscila Santos ; Rego, Eduardo Magalhães ; Pontes, Lorena Lôbo Figueiredo ; Machado Neto, João Agostinho ; Traina, Fabiola
Source: Toxicology in Vitro. Unidades: FM, FMRP, ICB
Subjects: FARMACOLOGIA, ANTINEOPLÁSICOS, INIBIDORES QUÍMICOS, MEDULA ÓSSEA, CÉLULAS-TRONCO, PROLIFERAÇÃO CELULAR, APOPTOSE, MUTAÇÃO, CÉLULAS MIELOIDES, FATORES DE CRESCIMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERNANDES, Jaqueline Cristina et al. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells. Toxicology in Vitro, v. 83, p. 1-7, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.tiv.2022.105384. Acesso em: 16 nov. 2024.
APA
Fernandes, J. C., Fenerich, B. A., Silva, A. B. A., Fonseca, N. P., Silva, J. L. C., Scheucher, P. S., et al. (2022). Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells. Toxicology in Vitro, 83, 1-7. doi:10.1016/j.tiv.2022.105384
NLM
Fernandes JC, Fenerich BA, Silva ABA, Fonseca NP, Silva JLC, Scheucher PS, Rego EM, Pontes LLF, Machado Neto JA, Traina F. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells [Internet]. Toxicology in Vitro. 2022 ; 83 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.tiv.2022.105384
Vancouver
Fernandes JC, Fenerich BA, Silva ABA, Fonseca NP, Silva JLC, Scheucher PS, Rego EM, Pontes LLF, Machado Neto JA, Traina F. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells [Internet]. Toxicology in Vitro. 2022 ; 83 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.tiv.2022.105384
Artigo de periodico
Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms (2022)
Cacemiro, Maira da Costa ; Cominal, Juçara Gastaldi ; Pereira, Luiz Miguel ; Berzoti-Coelho, Maria Gabriela ; Berbel, Giovana Michelassi; Baroni, Luciana ; Pereira, Tathiane Maistro Malta ; Tognon, Raquel; Nunes, Natália de Souza ; Souto, Elizabeth Xisto; Pontes, Lorena Lobo de Figueiredo ; Natsui, Ana Patrícia Yatsuda ; Castro, Fabíola Attié de
Source: Medical Oncology. Unidades: FCFRP, FMRP, ESALQ, FFCLRP, IQ
Subjects: APOPTOSE, EXPRESSÃO GÊNICA, HIPOTÁLAMO, NEOPLASIAS, PROLIFERAÇÃO CELULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CACEMIRO, Maira da Costa et al. Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms. Medical Oncology, v. 39, n. 5, p. 1-11, 2022Tradução . . Disponível em: https://doi.org/10.1007/s12032-022-01696-x. Acesso em: 16 nov. 2024.
APA
Cacemiro, M. da C., Cominal, J. G., Pereira, L. M., Berzoti-Coelho, M. G., Berbel, G. M., Baroni, L., et al. (2022). Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms. Medical Oncology, 39( 5), 1-11. doi:10.1007/s12032-022-01696-x
NLM
Cacemiro M da C, Cominal JG, Pereira LM, Berzoti-Coelho MG, Berbel GM, Baroni L, Pereira TMM, Tognon R, Nunes N de S, Souto EX, Pontes LL de F, Natsui APY, Castro FA de. Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms [Internet]. Medical Oncology. 2022 ; 39( 5): 1-11.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s12032-022-01696-x
Vancouver
Cacemiro M da C, Cominal JG, Pereira LM, Berzoti-Coelho MG, Berbel GM, Baroni L, Pereira TMM, Tognon R, Nunes N de S, Souto EX, Pontes LL de F, Natsui APY, Castro FA de. Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms [Internet]. Medical Oncology. 2022 ; 39( 5): 1-11.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s12032-022-01696-x
Artigo de periodico
Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms (2022)
Takei, Hisashi; Silva, Juan Luiz Coelho ; Leal, Cristina Tavares; Rocha, Adriana Queiroz Arantes; Bianco, Thiago Mantello ; Welner, Robert S.; Mishima, Yuta ; Kobayashi, Ikei S.; Mullally, Ann ; Lima, Keli Cristina de ; Machado Neto, João Agostinho ; Kobayashi, Susumu S. ; Pontes, Lorena Lobo De Figueiredo
Source: Cancer Science. Unidades: ICB, FMRP, FM
Subjects: FARMACOLOGIA, PROTEÍNAS PROTO-ONCOGÊNICAS, INIBIDORES DE ENZIMAS, MODELOS ANIMAIS DE DOENÇAS, FÁRMACOS, MEDICAMENTO, NEOPLASIAS, PROLIFERAÇÃO CELULAR, SOBREVIVÊNCIA CELULAR, CAMUNDONGOS, MUTAÇÃO, APOPTOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TAKEI, Hisashi et al. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Science, v. 113, n. 2, p. 1-12, 2022Tradução . . Disponível em: https://doi.org/10.1111/cas.15210. Acesso em: 16 nov. 2024.
APA
Takei, H., Silva, J. L. C., Leal, C. T., Rocha, A. Q. A., Bianco, T. M., Welner, R. S., et al. (2022). Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Science, 113( 2), 1-12. doi:10.1111/cas.15210
NLM
Takei H, Silva JLC, Leal CT, Rocha AQA, Bianco TM, Welner RS, Mishima Y, Kobayashi IS, Mullally A, Lima KC de, Machado Neto JA, Kobayashi SS, Pontes LLDF. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms [Internet]. Cancer Science. 2022 ; 113( 2): 1-12.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/cas.15210
Vancouver
Takei H, Silva JLC, Leal CT, Rocha AQA, Bianco TM, Welner RS, Mishima Y, Kobayashi IS, Mullally A, Lima KC de, Machado Neto JA, Kobayashi SS, Pontes LLDF. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms [Internet]. Cancer Science. 2022 ; 113( 2): 1-12.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/cas.15210
Artigo de periodico
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia (2021)
Ribeiro, Renata Scopim ; Machado Neto, João Agostinho ; Eide, Christopher A. ; Silva, Juan Luiz Coelho da ; Fenerich, Bruna Alves ; Fernandes, Jaqueline Cristina; Scheucher, Priscila Santos ; Stevens, Samantha L. Savage ; Campos, Paula de Melo; Saad, Sara T. Olalla ; Palma, Leonardo de Carvalho ; Pontes, Lorena Lobo de Figueiredo ; Simões, Belinda Pinto ; Rego, Eduardo Magalhães ; Tognon, Cristina E. ; Druker, Brian J. ; Traina, Fabiola
Source: Investigational New Drugs. Unidades: ICB, FMRP, FM
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE, INSULINA, ANTINEOPLÁSICOS, PROTEÍNAS QUINASES, CÉLULAS SANGUÍNEAS, PROLIFERAÇÃO CELULAR, APOPTOSE, ONCOGENES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIBEIRO, Renata Scopim et al. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, v. 39, n. 3, p. 736-746, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-020-01028-8. Acesso em: 16 nov. 2024.
APA
Ribeiro, R. S., Machado Neto, J. A., Eide, C. A., Silva, J. L. C. da, Fenerich, B. A., Fernandes, J. C., et al. (2021). NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, 39( 3), 736-746. doi:10.1007/s10637-020-01028-8
NLM
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Vancouver
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s10637-020-01028-8

USP Schools

ReP

Filtros

USP Schools

Authors

USP affiliated authors

Subjects

Funding Agencies

Indexado em

Non normalized affiliation